Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Invested Capital of $37944.0 for Q2 2025, down 75.07% year-over-year from $152224.0 in Q2 2024, and down 49.25% quarter-over-quarter from $74772.0 in Q1 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Invested Capital for 4 consecutive years, with $37944.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Invested Capital fell 75.07% year-over-year to $37944.0; the TTM figure through Mar 2026 stood at $37944.0 (down 92.14% YoY), while the FY2024 annual figure was $110517.0, down 26.37% from the prior year.
- Invested Capital retreated to $37944.0 in Q2 2025 per IKT's latest filing, from $74772.0 in the prior quarter.
- Across five years, Invested Capital topped out at $152224.0 in Q2 2024 and bottomed at $37944.0 in Q2 2025.
- Historically, Invested Capital has averaged $129475.2 across 4 years, with a median of $146368.5 in 2022.
- Annual changes were most pronounced in 2023 — Invested Capital climbed 4.92% — and 2025, when it tumbled 75.07%.
- Inhibikase Therapeutics' Invested Capital stood at $145836.0 in 2022, then grew by 2.92% to $150095.0 in 2023, then retreated by 26.37% to $110517.0 in 2024, then plunged by 65.67% to $37944.0 in 2025.
- Business Quant data shows IKT's Invested Capital at $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 172.90 Mn |
| Sep 30, 2025 | 72.90 Mn |
| Jun 30, 2025 | 80.09 Mn |
| Mar 31, 2025 | 85.81 Mn |
| Dec 31, 2024 | 94.98 Mn |
| Sep 30, 2024 | -385,381.00 |
| Jun 30, 2024 | 5.25 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Dec 31, 2023 | 11.51 Mn |
| Sep 30, 2023 | 15.17 Mn |
| Jun 30, 2023 | 19.61 Mn |
| Mar 31, 2023 | 25.43 Mn |
| Dec 31, 2022 | 21.18 Mn |
| Sep 30, 2022 | 25.28 Mn |
| Jun 30, 2022 | 29.50 Mn |
| Mar 31, 2022 | 34.01 Mn |
| Dec 31, 2021 | 38.91 Mn |
| Sep 30, 2021 | 43.66 Mn |
| Jun 30, 2021 | 47.30 Mn |
| Mar 31, 2021 | 10.28 Mn |